A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"

Sarika Ogale; Clarissa Emy Higuchi Zerbini; Miranta Antoniou; Romain Freund

doi:10.18553/jmcp.2020.26.12.1616

A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"

J Manag Care Spec Pharm. 2020 Dec;26(12):1616-1617. doi: 10.18553/jmcp.2020.26.12.1616.

Authors

Sarika Ogale¹, Clarissa Emy Higuchi Zerbini², Miranta Antoniou², Romain Freund²

Affiliations

¹ Genentech South Francisco, CA.
² F. Hoffmann-La Roche Basel, Switzerland.

Abstract

DISCLOSURES: The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.

Publication types

Letter
Comment

MeSH terms

Benzamides
Humans
Indazoles
Lung Neoplasms*
Protein Kinase Inhibitors*
Pyrazoles
Pyrimidines

Substances

Benzamides
Indazoles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
entrectinib
larotrectinib